Communication & Advocacy

A selection of communication and advocacy activities.

Research Priorities for an HIV Cure: IAS Global Scientific Strategy 2021 – The science in context © International AIDS Society

This document was written to translate the Research priorities for an HIV cure: International AIDS Society Global Scientific Strategy 2021 into a lay summary. Working with a fellow community-based organisation and a group of community advisors, I coordinated and co-produced this brief.

An HIV Vaccine: An Unfulfilled Promise?

This podcast series, produced in collaboration with the Global HIV Vaccine Enterprise at The International AIDS Society, features conversations between world-renowned guests about HIV vaccine development, HIV advocacy, and HIV policy to bust myths and address arguments for why an HIV vaccine is still needed and how we can continue working toward this ultimate game-changer for durable control of the HIV epidemic.

(Provided by Clinical Care Options, LLC).

Innovation in a pandemic: 40 years of HIV to the rescue?

COVID-19: Building on the HIV response to introduce innovation in a pandemic.

With a presentation by Prof Sharon Lewin, IAS Governing Council representative, Asia and the Pacific Islands, and Director, Peter Doherty Institute for Infection and Immunity, University of Melbourne and Royal Melbourne Hospital, Australia Oral testimonies.

Oral testimonies from:

Philippe Jacon, Senior Vice President Global Access, Cepheid, France.
Dr Jim Rooney, Vice President of Clinical Research, Gilead, USA.
Dr Mookho Malahleha, Co-principal Investigator, HVTN 702, and Deputy Director, Setshaba Research Centre, South Africa.
Maureen Luba Milambe, Africa Region Advocacy Advisor, AIDS Vaccine Advocacy Coalition (AVAC), Enterprise Advisory Group Member, VARG, Malawi.

Moderator: Roger Tatoud, International AIDS Society.

Making monoclonal antibodies broadly accessible to communities most at risk of HIV/AIDS – what would it take?’

The Webinar features an introduction from Mark Feinberg, CEO and President of IAVI, interviewed by Chloe Orkin, Clinical Professor of HIV Medicine at Queen Mary University of London, and chair of the British HIV Association (BHIVA), followed by perspectives of a renowned panel of experts on R&D, manufacturing, access, policy and regulation, and an audience Q&A. Panel includes:

Mike Cohen, Director, Institute for Global Health and Infectious Diseases, UNC School of Medicine, USA.
Helen Rees, Executive Director of the Wits Reproductive Health and HIV Institute at the University of the Witwatersrand, South Africa.
Rosemary Mburu, Executive Director WACI Health, Kenya.
Erin Sparrow, Technical Officer, Vaccine Product and Delivery Research Immunization, vaccines and Biologicals, World Health Organization, Geneva.
Bill Snow, Independent.
Co-Chair: Hester Kuipers (IAVI) and Roger Tatoud (Enterprise – International AIDS Society).

How HIV Vaccine R&D is enabling the rapid COVID-19 vaccine response.

In this presentation at the Research for Prevention virtual conference (2021), I presented the findings of report commissioned by the Global HIV Vaccine Enterprise on how investment in HIV vaccine Research and Development (R&D) has enabled the rapid advancement of COVID-19 vaccine R&D.

Developing an effective HIV vaccine: what do we need and when will we get there?

First attempts to develop a vaccine against HIV started in the 1980s. Thirty years on and we still do not have a viable vaccine. Why has it been so difficult? What is needed to realise the goal of an effective vaccine? Is the development of a vaccine still a priority? Researchers from EAVI2020 – a €23 million EU-funded research initiative to accelerate the search for an effective HIV vaccine – tackled these challenging questions in a roundtable discussion as part of EAVI2020’s annual meeting in October 2019.

Panellists include:

Facilitator, Dr Roger Tatoud – International AIDS Society.
Prof Robin Shattock – Imperial College London.
Dr Roger le Grand – Commissariat à l’ énergie atomique et aux énergies alternatives (CEA).
Susan Barnett – Bill & Melinda Gates Foundation.
Athina Kilpelainen – Vall d’Hebron Institut de Recerca.